{"id":937284,"date":"2026-02-17T12:00:19","date_gmt":"2026-02-17T17:00:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026\/"},"modified":"2026-02-17T12:00:19","modified_gmt":"2026-02-17T17:00:19","slug":"rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-thursday-february-26-2026\/","title":{"rendered":"Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026"},"content":{"rendered":"
\n

BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Thursday, February 26, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.<\/p>\n

To access the live conference call, participants may register\u00a0here<\/a>. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.<\/p>\n

Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in\u00a0Boston\u00a0on\u00a0Monday, March 2, 2026, at\u00a011:10 a.m. ET.<\/p>\n

Live webcasts of both the financial results conference call and the fireside chat will be available under “Events and Presentations” in the Investor Relations section of the Rhythm Pharmaceuticals website at http:\/\/ir.rhythmtx.com\/<\/a>. The archived webcast of the financial results conference call will be available on Rhythm\u2019s website approximately two hours after it concludes and will be available for 30 days following the call. A replay of the TD Cowen webcast will also be available on the Rhythm website for 30 days following the presentation.<\/p>\n

\n About Rhythm\u00a0Pharmaceuticals<\/strong>\u00a0
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm\u2019s lead asset, IMCIVREE\u00ae\u00a0<\/sup>(setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin\/kexin\u00a0type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK\u2019s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized\u00a0setmelanotide\u00a0for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for\u00a0setmelanotide\u00a0in other rare diseases, as well as investigational MC4R agonists bivamelagon\u00a0and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm\u2019s headquarters is in Boston, MA.\u00a0<\/p>\n

\n Setmelanotide\u00a0Indication<\/strong>\u00a0
In the United States,\u00a0setmelanotide\u00a0is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin\/kexin\u00a0type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).\u00a0<\/p>\n

In the European Union and the United Kingdom,\u00a0setmelanotide\u00a0is\u00a0indicated\u00a0for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom,\u00a0setmelanotide\u00a0should be prescribed and supervised by a physician with\u00a0expertise\u00a0in obesity with underlying genetic etiology.\u00a0<\/p>\n

\n Limitations of Use<\/strong>\u00a0
Setmelanotide\u00a0is not\u00a0indicated\u00a0for the treatment of patients with the following conditions as\u00a0setmelanotide\u00a0would not be expected to be effective:\u00a0<\/p>\n